Aspen Pharmacare announced that it has reached a “full and final settlement” of R500m to be paid before 1 December 2025, reported Business Day (3 Nov 2025).
This follows a “period of intense pressure for the company”, which began in April when Aspen first warned of a "material contractual dispute" related to an mRNA product manufacturing agreement.
“The company has not disclosed the identity of the counterparty, citing contractual confidentiality regarding the manufacturing and technology agreement.”